TG Therapeutics Highlights BRIUMVI® Data in Patients with Relapsing Forms of Multiple Sclerosis at CMSC 2025 Annual Meeting

TG Therapeutics presented new data at the 2025 CMSC annual meeting highlighting the efficacy and safety profile of BRIUMVI® (ublituximab-xiiy) in relapsing multiple sclerosis (RMS) patients. The presentations focused on long-term safety, infusion tolerability with 30-minute infusions, and the lack of association between immunoglobulin level decreases and serious infections; however, the data also acknowledged potential risks including infusion reactions and infection-related deaths observed in clinical trials. Institutional investors have shown mixed activity in $TGTX, with some increasing and others decreasing their positions.

Analysis

TG Therapeutics (TGTX) presented new data for its relapsing multiple sclerosis (RMS) treatment, BRIUMVI®, at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, aiming to bolster its clinical profile. Key presentations highlighted positive findings, including a lack of association between decreased serum immunoglobulin levels and serious infections during long-term treatment, and favorable safety and tolerability data for 30-minute infusions from the ENHANCE study. These developments, coupled with existing regulatory approvals from the FDA, European Commission, and UK authorities, support BRIUMVI's potential for increased adoption. However, significant safety concerns persist, notably a 48% incidence of infusion reactions and a 5% rate of serious infections, with three infection-related deaths reported in clinical trials. The requirement for vigilant monitoring for potential side effects such as Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) reactivation also adds complexity to its use. Market signals reflect a cautious outlook: the company's CFO executed two sales totaling 21,358 shares (estimated $629,382) in the past six months with no insider purchases. Institutional ownership changes in the most recent quarter were mixed, with 189 funds adding TGTX shares and 204 decreasing positions; notable movements included State Street Corp reducing its holding by 19.2% (1.77 million shares) and Deep Track Capital LP exiting its entire position (1.73 million shares in Q4 2024), while Wellington Management Group LLP substantially increased its stake by 1809.9% (1.15 million shares) in Q1 2025. This mixed institutional sentiment and insider activity, alongside the drug's risk-benefit profile, contribute to an overall mixed and cautious sentiment for TGTX.

Key Decisions for Investors

• Evaluate the commercial trajectory of BRIUMVI® by monitoring its market penetration and physician uptake, considering both its demonstrated efficacy and convenience benefits against its significant safety warnings, including a 48% infusion reaction rate and 5% serious infection rate.
• Closely scrutinize upcoming post-marketing surveillance data and any further clinical updates for BRIUMVI®, as these will be crucial in assessing the long-term viability and competitive positioning of the drug in the RMS market.
• Factor in the recent insider sales by the CFO and the divergent institutional investment activities, such as significant position reductions by firms like State Street and Opaleye Management versus substantial increases by Wellington Management and Clearbridge Investments, when assessing the current risk/reward profile for TG Therapeutics.